Format

Send to

Choose Destination
Vaccine. 2015 Dec 10;33(50):7100-11. doi: 10.1016/j.vaccine.2015.09.108. Epub 2015 Oct 20.

Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.

Author information

1
Research and Development, Sanofi Pasteur, 69007 Lyon, France. Electronic address: bruno.guy@sanofipasteur.com.
2
Industrial Operations, Sanofi Pasteur, 69007 Lyon, France.
3
Research and Development, Sanofi Pasteur, 69007 Lyon, France.

Abstract

Sanofi Pasteur has developed a recombinant, live-attenuated, tetravalent dengue vaccine (CYD-TDV) that is in late-stage development. The present review summarizes the different steps in the development of this dengue vaccine, with a particular focus on the clinical data from three efficacy trials, which includes one proof-of-concept phase IIb (NCT00842530) and two pivotal phase III efficacy trials (NCT01373281 and NCT01374516). Earlier studies showed that the CYD-TDV candidate had a satisfactory safety profile and was immunogenic across the four vaccine serotypes in both in vitro and in vivo preclinical tests, as well as in initial phase I to phase II clinical trials in both flavivirus-naïve and seropositive individuals. Data from the 25 months (after the first injection) active phase of the two pivotal phase III efficacy studies shows that CYD-TDV (administered at 0, 6, and 12 months) is efficacious against virologically-confirmed disease (primary endpoint) and has a good safety profile. Secondary analyses also showed efficacy against all four dengue serotypes and protection against severe disease and hospitalization. The end of the active phases in these studies completes more than a decade of development of CYD-TDV, but considerable activities and efforts remain to address outstanding scientific, clinical, and immunological questions, while preparing for the introduction and use of CYD-TDV. Additional safety observations were recently reported from the first complete year of hospital phase longer term surveillance for two phase 3 studies and the first and second completed years for one phase 2b study, demonstrating the optimal age for intervention from 9 years. Dengue is a complex disease, and both short-term and long-term safety and efficacy will continue to be addressed by ongoing long-term follow-up and future post-licensure studies.

KEYWORDS:

Dengue; Tetravalent dengue vaccine; Vaccine; flavivirus

PMID:
26475445
DOI:
10.1016/j.vaccine.2015.09.108
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center